The Psyence™ Group sets the global standard for natural psychedelics.
Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.
We are focused on the scientific research and development of psilocybin medical products for research institutions, clinics and regulatory-compliant psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.
Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.
The Psyence™ Group sets the global standard for natural psychedelics.
Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.
We are focused on the scientific research and development of psilocybin medical products for research institutions, clinics and regulatory-compliant psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.
Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and on the US OTCQB® Venture Market (OTCQB: PSYGF). Our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.
Psyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.
We develop natural psilocybin products,
medicinal formulations and treatment protocols
to treat mental health disorders in a clinical environment.
Learn More
We will partner with experienced providers of retreats
and clinics in legal jurisdictions to inform our medical
and product development strategy.
Learn More
With experience in building disruptive brands and creating
routes to market, we are focused on the development
of over-the-counter proprietary nutraceutical products.
Learn More
We operate one of the first federally licensed commercial
psilocybin cultivation and production facilities in the world.
Learn MorePsyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.
Bringing together leaders in the business of medicine and science
Our scientific and medical team, which includes experts in neurology, neuroscience, oncology and drug development, have international expertise in palliative medicine and science. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Bringing together leaders in the business of medicine and science
Our scientific and medical team, which includes experts in neurology, neuroscience, oncology and drug development, have international expertise in palliative medicine and science. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit
Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing.
Covid-19 steepens the trajectory of an already booming functional mushroom market
Covid-19 steepens the trajectory of an already booming functional [...]
In conversation with Neil van Rij on Psyence’s magic mushrooms
Neil van Rij is Psyence’s resident mycologist. In this interview he sheds some light on the mushrooms Psyence is growing at its state-of-the-art facility in Lesotho and what these mushrooms will be used for.
Our News
Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit
Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing.
Covid-19 steepens the trajectory of an already booming functional mushroom market
Covid-19 steepens the trajectory of an already booming functional [...]
In conversation with Neil van Rij on Psyence’s magic mushrooms
Neil van Rij is Psyence’s resident mycologist. In this interview he sheds some light on the mushrooms Psyence is growing at its state-of-the-art facility in Lesotho and what these mushrooms will be used for.